Navigation Links
Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy

MONTPELLIER, France, Dec. 4 /PRNewswire-FirstCall/ -- A 60-year-old prostate cancer patient from Montpellier has become the first person in France to be treated using RapidArc(TM) technology from Varian Medical Systems (NYSE: VAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val D'Aurelle - Paul Lamarque in the city took just 75 seconds, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospital's chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 12- 14.

"The treatments went extremely well and the patient was very pleased because compared to conventional IMRT it was three times quicker," Dr. Fenoglietto said. "We are now able to use the time we save on treatment delivery to take more images and increase the quality of our care."

"The radiation therapists were also very pleased because it is a simpler treatment for them to deliver," added Professor Jean-Bernard Dubois, head of the radiation oncology department and managing director of the hospital.

With RapidArc, Varian's Clinac(R) medical linear accelerator can target radiation beams at a tumor while making one continuous rotation around the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers because they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more control to conform the dose more closely to the size, shape, and location of the tumor. Faster treatment also contributes to precision by reducing the time for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. "With this technology we have the opportunity to improve outcomes while offering more patients greater access to advanced care," Dr. Fenoglietto said. "We're excited to be the first hospital in France and the fourth in Europe to offer this treatment to patients."

The hospital, one of the seven members of Varian's RapidArc Council of pioneering centers that helped develop the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the department using French-language treatment planning and oncology information management software. More than 700 patients have been treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo, "Pelvic cases can take between 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs around the patient with RapidArc. If we do this, there is less possibility for the patient to move and we reduce the chance of internal motion playing a part, as there tends to be a lot of motion in the pelvic region. Also, fast treatments reduce the possibility of inaccuracy and increase patient comfort."

RapidArc delivers a volumetric intensity-modulated radiation therapy treatment in a single or multiple arcs of the treatment machine around the patient and makes it possible to deliver advanced image-guided IMRT two to eight times faster than is possible with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,800 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
2. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
3. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
6. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
9. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
10. When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer
11. American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Post Your Comments:
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... 2015 , ... Whitehouse Laboratories is pleased to announce that it has completed ... strictly dedicated to basic USP 61, USP 62 and USP 51 testing specific to ... chemistry and micro testing performed by one supplier. Management has formally announced ...
(Date:11/23/2015)... Ceres, Inc . (Nasdaq: CERE ), an agricultural ... year ended August 31, 2015 and provided an update ... --> During fiscal year 2015, Ceres refocused its ... better balance of yield, energy and nutrition. Among other ... crop input providers and made significant progress in advancing ...
(Date:11/23/2015)... , ... November 23, 2015 , ... Noblis, Inc., a ... former Director, Plans and Programs, National Geospatial Intelligence Agency (NGA), has joined the Noblis ... an incredibly distinguished career in the intelligence community and the private sector,” said ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):